Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5199134
Max Phase: Preclinical
Molecular Formula: C18H29N5O2S
Molecular Weight: 379.53
Associated Items:
ID: ALA5199134
Max Phase: Preclinical
Molecular Formula: C18H29N5O2S
Molecular Weight: 379.53
Associated Items:
Canonical SMILES: CC(=O)Nc1ncc(CN2CCN(CC(=O)NC3CCCCC3)CC2)s1
Standard InChI: InChI=1S/C18H29N5O2S/c1-14(24)20-18-19-11-16(26-18)12-22-7-9-23(10-8-22)13-17(25)21-15-5-3-2-4-6-15/h11,15H,2-10,12-13H2,1H3,(H,21,25)(H,19,20,24)
Standard InChI Key: VXSBPUHYZOSXTM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 379.53 | Molecular Weight (Monoisotopic): 379.2042 | AlogP: 1.67 | #Rotatable Bonds: 6 |
Polar Surface Area: 77.57 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.01 | CX Basic pKa: 5.79 | CX LogP: 1.17 | CX LogD: 1.07 |
Aromatic Rings: 1 | Heavy Atoms: 26 | QED Weighted: 0.79 | Np Likeness Score: -2.13 |
1. Li X, Han J, Bujaranipalli S, He J, Kim EY, Kim H, Im JH, Cho WJ.. (2022) Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease., 238 [PMID:35588599] [10.1016/j.ejmech.2022.114444] |
Source(1):